EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Photobiomodulation therapy increases neural stem cell pool in aged 3xTg-AD mice

Kevin J Johnson iD, Kathia Johnson, Auston Grant, Giulio Taglialatela, Maria-Adelaide Micci iD

PLOS ONE · 2025

DOI: 10.1371/journal.pone.0321668 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Kevin J Johnson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, University of Texas Medical Branch, Galveston, Texas, United States of America. Hauptthemen laut MEDLINE: Alzheimer Disease, Low-Level Light Therapy, Neural Stem Cells, Aging. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NIH HHS, National Institute of Aging.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Presently approved Alzheimer’s Disease (AD) therapeutics are designed for targeted removal of the AD-related toxic protein aggregate amyloid-β (Aβ) and have only shown moderate efficacy at slowing disease progression. Reversal of cognitive decline requires both removal of toxic aggregates and repair of the cellular systems damaged by decades of exposure to these aggregates. Adult hippocampal neurogenesis (AHN) is one such system that is known to be affected early and severely in the development of AD. Moreover, preserved AHN is associated with cognitive resilience to AD neuropathology. Therefore, targeted therapies to improve or enhance neurogenesis should be considered in addition to the removal of toxic protein aggregates. Photobiomodulation (PBM) using 670 nm LED light has been shown to induce synaptic resilience to and removal of AD-related toxic protein aggregates. In this study, we aimed to assess the effect of PBM on a mouse model of advanced AD neuropathology. Transgenic 3xTg-AD mice (15- to 17-month old) were randomized to receive PBM or SHAM therapy for one month, followed by neuropathological assessments. Our results show that one month of PBM therapy reduces hyperphosphorylated tau burden and partially rescues AHN in aged 3xTg-AD mice as compared to SHAM-treated transgenic mice. These data support the notion that PBM has the potential to be an effective non-invasive therapy to help preserve AHN and reduce cognitive dysfunction in moderate to advanced AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseLow-Level Light TherapyNeural Stem CellsAgingAnimalsMice, TransgenicMiceNeurogenesisHippocampusDisease Models, Animaltau Proteins

Substanzen

tau Proteins

Autor:innen und Institutionen

  • Department of Anesthesiology, University of Texas Medical Branch, Galveston, Texas, United States of America.
  • Department of Neurobiology, Neuroscience Graduate Program, University of Texas Medical Branch, Galveston, Texas, United States of America.
  • The Mitchell Center for Neurodegenerative Disorders, Department of Neurology, University of Texas Medical Branch, Galveston, Texas, United States of America.

ORCID-Profile: Kevin J Johnson, Maria-Adelaide Micci

Förderung

  • NIA NIH HHS
  • NIH HHS
  • National Institute of Aging
  • National Institute of Health

Zitieren

APA

Johnson, K. J., Johnson, K., Grant, A., Taglialatela, G., & Micci, M. A. (2025). Photobiomodulation therapy increases neural stem cell pool in aged 3xTg-AD mice. PLOS ONE. https://doi.org/10.1371/journal.pone.0321668

Vancouver

Johnson KJ, Johnson K, Grant A, Taglialatela G, Micci MA. Photobiomodulation therapy increases neural stem cell pool in aged 3xTg-AD mice. PLOS ONE. 2025. doi:10.1371/journal.pone.0321668

BibTeX
@article{Johnson2025,
  author = {Johnson, Kevin J and Johnson, Kathia and Grant, Auston and Taglialatela, Giulio and Micci, Maria-Adelaide},
  title = {Photobiomodulation therapy increases neural stem cell pool in aged 3xTg-AD mice},
  journal = {PLOS ONE},
  year = {2025},
  doi = {10.1371/journal.pone.0321668}
}
Kostenlos starten →